• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Is chemotherapy for advanced or metastatic oesophageal squamous cell carcinoma no longer needed?

作者信息

van Laarhoven Hanneke Wm

机构信息

Department of Medical Oncology, Cancer Center Amsterdam, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam D3-312 1105, Netherlands.

出版信息

Lancet Oncol. 2020 Jun;21(6):743-745. doi: 10.1016/S1470-2045(20)30182-0.

DOI:10.1016/S1470-2045(20)30182-0
PMID:32502437
Abstract
摘要

相似文献

1
Is chemotherapy for advanced or metastatic oesophageal squamous cell carcinoma no longer needed?晚期或转移性食管鳞状细胞癌不再需要化疗了吗？
Lancet Oncol. 2020 Jun;21(6):743-745. doi: 10.1016/S1470-2045(20)30182-0.
2
ASO Author Reflections: Prognostic Stratification and the Value of Adjuvant Therapy in Thoracic Esophageal Squamous Cell Carcinoma Patients After Esophagectomy.ASO作者反思：胸段食管鳞状细胞癌患者食管切除术后的预后分层及辅助治疗的价值
Ann Surg Oncol. 2019 Dec;26(Suppl 3):802-803. doi: 10.1245/s10434-019-07728-7. Epub 2019 Oct 25.
3
Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial.纳武利尤单抗对比化疗用于既往化疗后进展或不耐受的晚期食管鳞癌患者（ATTRACTION-3）：一项多中心、随机、开放标签、III 期临床研究。
Lancet Oncol. 2019 Nov;20(11):1506-1517. doi: 10.1016/S1470-2045(19)30626-6. Epub 2019 Sep 30.
4
Level I evidence in support of perioperative chemotherapy for operable gastric cancer: sufficient for wide clinical use?支持可手术胃癌围手术期化疗的一级证据：是否足以广泛应用于临床？
Ann Surg Oncol. 2007 Oct;14(10):2691-5. doi: 10.1245/s10434-007-9358-z. Epub 2007 Jul 26.
5
[Efficacy analysis of the radiotherapy and chemotherapy in patients with stage Ⅳ esophageal squamous carcinoma: a multicenter retrospective study of Jing-Jin-Ji Esophageal and Esophagogastric Cancer Radiotherapy Oncology Group (3JECROG R-01F)].[Ⅳ期食管鳞癌患者放化疗疗效分析：京津冀食管癌和食管胃交界癌放疗肿瘤学组（3JECROG R-01F）多中心回顾性研究]
Zhonghua Zhong Liu Za Zhi. 2020 Aug 23;42(8):676-681. doi: 10.3760/cma.j.cn112152-20190327-00197.
6
Prognostic Factors for Esophageal Squamous Cell Carcinoma Treated with Neoadjuvant Docetaxel/Cisplatin/5-Fluorouracil Followed by Surgery.新辅助多西他赛/顺铂/氟尿嘧啶治疗后手术治疗食管鳞癌的预后因素。
Oncology. 2019;97(6):348-355. doi: 10.1159/000502342. Epub 2019 Aug 28.
7
Outcomes and Prognostic Factors of Patients with Unresectable or Metastatic Esophageal Squamous Cell Carcinoma Undergoing Immunotherapy- Versus Chemotherapy-Based Regimens: Systematic Review and Pooled Analyses.不可切除或转移性食管鳞癌患者接受免疫治疗与化疗方案的结局和预后因素：系统评价和汇总分析。
J Gastrointest Cancer. 2024 Dec;55(4):1541-1550. doi: 10.1007/s12029-024-01100-z. Epub 2024 Aug 17.
8
Sex differences in the prognosis after surgery for esophageal squamous cell carcinoma and adenocarcinoma.食管鳞癌和腺癌手术后预后的性别差异。
Int J Cancer. 2019 Mar 15;144(6):1284-1291. doi: 10.1002/ijc.31840. Epub 2018 Oct 31.
9
Phase II Study of S-1 plus Cisplatin as First-Line Therapy in Patients with Metastatic Esophageal Carcinoma.S-1 联合顺铂一线治疗转移性食管癌的 II 期研究。
Oncol Res Treat. 2019;42(3):115-122. doi: 10.1159/000495700. Epub 2019 Feb 23.
10
Safety and efficacy of tislelizumab plus chemotherapy for first-line treatment of advanced esophageal squamous cell carcinoma and gastric/gastroesophageal junction adenocarcinoma.替雷利珠单抗联合化疗用于一线治疗晚期食管鳞状细胞癌和胃/胃食管交界腺癌的安全性和有效性。
Thorac Cancer. 2020 Dec;11(12):3419-3421. doi: 10.1111/1759-7714.13690. Epub 2020 Oct 12.

引用本文的文献

1
Cost‑effectiveness analysis of tislelizumab plus chemotherapy in Chinese patients with advanced or metastatic oesophageal squamous cell carcinoma.替雷利珠单抗联合化疗治疗中国晚期或转移性食管鳞癌患者的成本-效果分析。
Sci Rep. 2024 Jul 31;14(1):17734. doi: 10.1038/s41598-024-68399-3.
2
Targeting the mitochondrial calcium uniporter inhibits cancer progression and alleviates cisplatin resistance in esophageal squamous cell carcinoma.靶向线粒体钙单向转运蛋白抑制食管鳞癌的进展并缓解顺铂耐药性。
Int J Oncol. 2023 Jul;63(1). doi: 10.3892/ijo.2023.5530. Epub 2023 Jun 2.
3
Comparative efficacy and toxicity of immune checkpoint inhibitors in combination with or without chemotherapy treatment for advanced esophageal squamous cell carcinoma: A systematic review and meta-analysis.
免疫检查点抑制剂联合或不联合化疗治疗晚期食管鳞状细胞癌的疗效和毒性比较：一项系统评价和荟萃分析
Front Oncol. 2022 Nov 24;12:958783. doi: 10.3389/fonc.2022.958783. eCollection 2022.
4
Local Ablative Treatment Improves Survival in ESCC Patients With Specific Metastases, 2010-2016: A Population-Based SEER Analysis.局部消融治疗可提高2010 - 2016年特定转移的食管癌患者生存率：一项基于人群的监测、流行病学和结果（SEER）分析
Front Oncol. 2022 Jun 16;12:783752. doi: 10.3389/fonc.2022.783752. eCollection 2022.
5
Integrated analysis of immune infiltration in esophageal carcinoma as prognostic biomarkers.食管癌免疫浸润作为预后生物标志物的综合分析
Ann Transl Med. 2021 Nov;9(22):1697. doi: 10.21037/atm-21-5881.
6
Knockdown of GBAS regulates esophageal cancer cell viability and apoptosis.GBAS 的敲低调节食管癌细胞活力和凋亡。
Mol Med Rep. 2021 Jul;24(1). doi: 10.3892/mmr.2021.12162. Epub 2021 May 26.